SCHEMBL10141691

SCHEMBL10141691

CCNC(=O)c1cncc(C(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 3/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
PKM P14618 1/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ATM Q13315 1/20 0.41
HPGDS O60760 1/20 0.41
TP53 P04637 2/20 0.40
MAPK1 P28482 2/20 0.40
CASP3 P42574 1/20 0.40
MAPT P10636 1/20 0.40
ALPL P05186 1/20 0.40
CYP3A4 P08684 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10141685 0.88 PKM (0.48) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL13466415 0.84 KDM4E (0.48) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL18948350 0.82 ULK1 (0.44) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL13467100 0.82 LMNA (0.50) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL799384 0.81 GAA (0.46) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL13130434 0.81 HPGD (0.53) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL25820302 0.80 XDH (0.56) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL5426126 0.78 HCAR2 (0.56) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL3824227 0.78 KDM4E (0.69) KDM4EALDH1A1GAALMNAMEN1
SCHEMBL26306821 0.78 MEN1 (0.40) KDM4EALDH1A1HSD17B10GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858360-B2 Tricyclic gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-08 US disclosed
US-20170260175-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED 2017-09-14 US disclosed
US-9676759-B2 Isoindolinone inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-06-13 US disclosed
US-20140038936-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED 2014-02-06 US disclosed
US-8466288-B2 Isoindolinone inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-18 US disclosed
US-20120202784-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-09 US disclosed
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140038936-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CD, PIK3CA, PIK3R5 KDM4E 2889/4885ALDH1A1 3381/4885HSD17B10 1262/4885
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CD, PIK3CA, PIK3R5 KDM4E 2889/4885ALDH1A1 3381/4885HSD17B10 1262/4885
US-10858360-B2 Tricyclic gyrase inhibitors TOP1, TOP2A, TOP2B KDM4E 2371/4885ALDH1A1 1898/4885HSD17B10 356/4885
US-20120202784-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CD, PIK3CA, PIK3R5 KDM4E 2889/4885ALDH1A1 3381/4885HSD17B10 1262/4885
US-20170260175-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CD, PIK3CA, PIK3R5 KDM4E 2889/4885ALDH1A1 3381/4885HSD17B10 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.